Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer
Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.
Key wordsProstate cancer GEMMs Cell line derivation Cre-loxP recombination Mouse prostate dissection Genotyping Syngeneic
The authors would like to acknowledge the CCRCB laboratory personnel who have helped to optimize these protocols; in particular, we would like to acknowledge Dr. Adam Pickard, Dr. Sharon Eddie Parkinson, and Dr. Lara Dura Perez for their work on cell line derivation from the mouse prostate tissue.
- 2.Park SI, Kim SJ, McCauley LK, Gallick GE (2010) Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Enna SJ (editor-in-chief) et al. Curr Protoc Pharmacol; Chapter 14: Unit 14.15Google Scholar
- 9.Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305CrossRefPubMedGoogle Scholar